Results 221 to 230 of about 1,436,444 (347)

B cell receptor-based hybridoma enrichment enables discovery of antibodies against intracellular tumor antigens. [PDF]

Front Immunol
Dotan I, Raviv Y, Bublik DR, Kortendieck JA, Jain S, Glucksam Galnoy Y, Smorodinsky NI, Barzel A.   +7 more
europepmc   +1 more source

Intrinsic tumor cell line immunogenicity may drive CAR-independent T cell responses and confound CAR T cell preclinical modeling. [PDF]

J Immunother Cancer
Sheng MK, Firoz WA, Loi K, Vick LV, Collins CP, Nielsen RN, Schmeling JL, Gulati S, Judge SJ, Canter RJ, Monjazeb AM, Zamora AE, Murphy WJ.   +12 more
europepmc   +1 more source

Resistance mechanisms and overcoming strategies for CAR T-cell therapy in B-cell hematologic malignancies. [PDF]

Front Immunol
Li P, Xue X, Zhang Z.
europepmc   +1 more source

Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor

Cancer Gene Therapy, 2015
Harjeet Singh, J. Moyes, M. H. Huls, Laurence J. N. Cooper   +3 more
semanticscholar   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

CAR T cell therapy beyond cancer: current status, challenges and future prospects. [PDF]

Signal Transduct Target Ther
Upadhyay S, Cho S, Upmanyu K, Gabr MT.
europepmc   +1 more source

CD19 chimeric antigen receptor T cell therapy for haematological malignancies

British Journal of Haematology, 2015
S. Ghorashian, M. Pule, P. Amrolia
semanticscholar   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

Impact of Prior Exposure to Anisakis simplex Antigens on Immune Response During SARS-CoV-2 Vaccination. [PDF]

Parasite Immunol
Cuéllar C, Rodero M, González-Fernández J, Galindo-Regal L, López-Chuliá F, García-Ballesteros C, Fernández-Murga L, Llombart-Cussac A, Domínguez-Márquez MV, Andreu-Ballester JC.   +9 more
europepmc   +1 more source

Protein Corona‐Coated Crystal Silica From Sandstorms Amplifies Allergic Rhinitis by Regulating Epithelial Integrity in Mice and Human Nasal Epithelia

Allergy, EarlyView.
Cuishuang Dong, Xu Zhang, Haoyue Wang, Jiajing Cui, Shuai Han, Yibo Wang, Huanying Zhao, Yang Song, Yuan Zhang, Xiaobo Li   +9 more
wiley   +1 more source